Pemgarda Neutralizing Activity Remains Stable Against Current Dominant SARS-CoV-2 Strain

Pemivibart, a next-generation COVID-19 monoclonal antibody (mAb), is still showing clinically meaningful in vitro neutralization data against the currently dominant LP.8.1 variant of SARS-CoV-2, according to data provided to the company by the FDA.